Navigation Links
Two New Appointments at Meditor Pharmaceuticals Ltd.
Date:5/12/2008

REHOVOT, Israel, May 12 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today the appointment of Prof. Arie Schachner to serve as a Senior Medical Advisor to the company.

Dr. Schachner has been a member of Meditor's Scientific Advisory Board since 2001 and will now take a more active role in the Clinical Development program.

Prof. Schachner was the founder and Head of the Cardiac Surgery Department at Wolfson Medical Center and Tel Aviv University Sackler Medical School. He is an opinion leader in the Cardiac Surgery area, he is a distinguished member of several professional societies and has many publications in this field. Prof. Schachner will collaborate with recently appointed CEO, Dr. Adrian Harel, in the ongoing Phase II Clinical trial on Hypotension in patients undergoing Cardio Artery Bypass Graft (CABG) patients and in designing future clinical trials.

Dr. Adrian Harel joined Meditor in January 2008. He combines a broad scientific education with extensive industry experience. He holds a Ph.D. in Neurobiology, from the Weizmann Institute of Science, and was a postdoctoral at Washington University. Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Dr. Harel has extensive Drug research & development know-how and GMP production and manufacturing knowledge.

About Meditor Pharmaceuticals: Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of acute and chronic hypotension and hypotension-related disorders. The lead development compound is a unique low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. The clinical development program is focused on the development of lead compound MTR104 for the treatment of three main medical targets: MTR107 (i.v. formulation) for Intradialytic Hypotension, MTR106 (immediate release oral tablet formulation) for Migraine, and MTR105 (i.v. formulation) for the treatment of hypotension associated with cardiac surgery. Meditor's patent portfolio provides the company with a strong proprietary position in the U.S. and worldwide. For more information on the company and its drug development activities, please visit http://www.meditorpharma.com

For all inquiries please contact Mr. Rafi Barkan, Chairman at +972 8 930 3307 or Dr. Adrian Harel, CEO at +972 8 930 3305.


'/>"/>
SOURCE Meditor Pharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
2. QuoNova Global Executive Appointments
3. Senetek PLC Announces Appointments of Key Personnel
4. VLST Corporation Announces Board and Executive Management Appointments
5. Medefield Announces New Appointments to North American Business Unit
6. Access Genetics Announces New Executive Appointments
7. Genaera Elects New Board Member and Announces Executive Appointments
8. ADM Announces Appointments
9. Interleukin Genetics Announces Management and Board Appointments
10. Nitec Pharma AG Announces Appointments of CEO & CFO in Preparation for Launch of Lodotra(R)
11. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):